Summary Basis of Decision for Removab®

Health Canada has issued a Notice of Compliance to Fresenius Biotech GmbH for the drug product Removab. Removab contains the medicinal ingredient catumaxomab, a monoclonal antibody that acts as an antineoplastic agent. Removab is indicated for the palliative management of malignant ascites via intraperitoneal infusion in patients with epithelial cell adhesion molecule (EpCAM) positive carcinomas where standard therapy is not available or no longer feasible. Read more here.